Unexpected Death of a Duchenne Muscular Dystrophy Patient in an N-of-1 Trial of rAAV9-delivered CRISPR-transactivator
Lek, A.; Wong, B.; Keeler, A.; Blackwood, M.; Ma, K.; Huang, S.; Sylvia, K.; Batista, A. R.; Artinian, R.; Kokoski, D.; Parajuli, S.; Putra, J.; Carreon, C. K.; Lidov, H.; Woodman, K.; Pajusalu, S.; Spinazzola, J.; Gallagher, T.; LaRovere, J.; Baulderson, D.; Black, L.; Sutton, K.; Horgan, R.; Lek, M.; Flotte, T.
Show abstract
An N-of-1 trial was developed to deliver a dCas9-VP64 transgene designed to upregulate the cortical dystrophin as a custom therapy for a Duchenne muscular dystrophy (DMD) patient. After showing signs of mild cardiac dysfunction and pericardial effusion, the patient acutely decompensated and sustained cardiac arrest six-days after dosing and succumbed two-days later. Post-mortem examination revealed severe acute-respiratory distress syndrome with diffuse alveolar damage. Vector biodistribution data was obtained and revealed minimal expression of transgene in liver. There was no evidence of AAV9 antibodies nor of effector T cell reactivity. These findings demonstrate innate immune signaling with capillary leak as a form of toxicity in an advanced DMD case treated with high-dose rAAV gene therapy.
Matching journals
The top 2 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- AAV-mediated gene transfer restores a normal muscle transcriptome in a canine model of X-linked myotubular myopathy 94%
- Preclinical lentiviral vector-mediated hematopoietic stem and progenitor cell gene therapy corrects Pompe disease-related muscle and neurological manifestations 93%
- A Precision Gene Engineered B Cell Medicine Producing Sustained Levels of Active Factor IX for Hemophilia B Therapy 93%
Similar papers in this journal
- Screening of Chimeric GAA Variants in a Preclinical Study of Pompe Disease Results in Candidate Vector for Hematopoietic Stem Cell Gene Therapy 93%
- Efficient Gene Transduction in Pigs and Macaques with the Engineered AAV Vector AAV.GT5 for Hemophilia B Gene Therapy 92%
- High levels of frataxin overexpression leads to mitochondrial and cardiac toxicity in mouse models 92%
Similar papers in this journal
Similar papers in this journal
- Co-opting MBNL-dependent alternative splicing cassette exons to control gene therapy in myotonic dystrophy 95%
- RAN translation of C9orf72-related dipeptide repeat proteins in zebrafish recapitulates hallmarks of amyotrophic lateral sclerosis and identifies hypothermia as a therapeutic strategy 90%
- Fibroblast transcriptomics in molecular diagnostics of a comprehensive dystonia cohort 88%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.